Is QGEN or TYRA more profitable?

Qiagen has a net margin of 19.16% compared to Tyra Biosciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Tyra Biosciences N/A -42.66% -39.79%

Does the media favor QGEN or TYRA?

In the previous week, Qiagen had 4 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Qiagen and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Qiagen's score of -0.41 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PCVX or TYRA?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A Tyra Biosciences N/A N/A -$119.95M -$2.18 N/A

Is PCVX or TYRA more profitable?

Vaxcyte's return on equity of -32.51% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Tyra Biosciences N/A -42.66% -39.79%

Does the media prefer PCVX or TYRA?

In the previous week, Vaxcyte had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 5 mentions for Vaxcyte and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Vaxcyte's score of 0.21 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, TYRA or IMVT?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tyra Biosciences N/A N/A -$119.95M -$2.18 N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is TYRA or IMVT more profitable?

Tyra Biosciences' return on equity of -42.66% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -42.66% -39.79% Immunovant N/A -65.66% -59.88%

Does the media favor TYRA or IMVT?

In the previous week, Immunovant had 4 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Immunovant and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Immunovant's score of 0.43 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LNTH or TYRA more profitable?

Lantheus has a net margin of 18.05% compared to Tyra Biosciences' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Tyra Biosciences N/A -42.66% -39.79%

Does the media prefer LNTH or TYRA?

In the previous week, Lantheus had 2 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Lantheus' score of 0.54 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TYRA or KYMR?

In the previous week, Kymera Therapeutics had 2 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Kymera Therapeutics and 2 mentions for Tyra Biosciences. Kymera Therapeutics' average media sentiment score of 1.39 beat Tyra Biosciences' score of 0.93 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tyra Biosciences (TYRA) Competitors

$27.18 -1.51 (-5.26%)

Closing price 04:00 PM Eastern

Extended Trading

$27.01 -0.17 (-0.63%)

As of 06:55 PM Eastern

Compare

TYRA vs. QGEN, PCVX, IMVT, LNTH, and KYMR

Should you buy Tyra Biosciences stock or one of its competitors? MarketBeat compares Tyra Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tyra Biosciences include Qiagen (QGEN), Vaxcyte (PCVX), Immunovant (IMVT), Lantheus (LNTH), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Tyra Biosciences compare to Qiagen?

Qiagen (NYSE:QGEN) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Qiagen has a net margin of 19.16% compared to Tyra Biosciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Tyra Biosciences	N/A	-42.66%	-39.79%

Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Qiagen has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.70	$424.88M	$1.91	19.64
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Qiagen presently has a consensus target price of $44.98, indicating a potential upside of 19.92%. Tyra Biosciences has a consensus target price of $46.50, indicating a potential upside of 71.08%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

70.0% of Qiagen shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Qiagen had 4 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Qiagen and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Qiagen's score of -0.41 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Qiagen beats Tyra Biosciences on 8 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Vaxcyte has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Vaxcyte had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 5 mentions for Vaxcyte and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Vaxcyte's score of 0.21 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte's return on equity of -32.51% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Tyra Biosciences	N/A	-42.66%	-39.79%

Vaxcyte currently has a consensus target price of $86.00, suggesting a potential upside of 76.37%. Tyra Biosciences has a consensus target price of $46.50, suggesting a potential upside of 71.08%. Given Vaxcyte's higher possible upside, research analysts plainly believe Vaxcyte is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Tyra Biosciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Summary

Vaxcyte and Tyra Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to Immunovant?

Tyra Biosciences (NASDAQ:TYRA) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Tyra Biosciences' return on equity of -42.66% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Immunovant	N/A	-65.66%	-59.88%

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tyra Biosciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Tyra Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

In the previous week, Immunovant had 4 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Immunovant and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Immunovant's score of 0.43 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tyra Biosciences presently has a consensus target price of $46.50, suggesting a potential upside of 71.08%. Immunovant has a consensus target price of $37.33, suggesting a potential upside of 14.27%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Tyra Biosciences is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Tyra Biosciences beats Immunovant on 11 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Lantheus has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.33	$233.56M	$4.15	24.78
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Lantheus presently has a consensus price target of $101.86, indicating a potential downside of 0.94%. Tyra Biosciences has a consensus price target of $46.50, indicating a potential upside of 71.08%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Lantheus had 2 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Lantheus' score of 0.54 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Tyra Biosciences' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Tyra Biosciences	N/A	-42.66%	-39.79%

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lantheus beats Tyra Biosciences on 9 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Kymera Therapeutics?

Tyra Biosciences (NASDAQ:TYRA) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Tyra Biosciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Tyra Biosciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

Tyra Biosciences presently has a consensus target price of $46.50, indicating a potential upside of 71.08%. Kymera Therapeutics has a consensus target price of $118.10, indicating a potential upside of 58.28%. Given Tyra Biosciences' higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

84.1% of Tyra Biosciences shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tyra Biosciences has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Kymera Therapeutics	$39.21M	156.53	-$311.35M	-$3.57	N/A

In the previous week, Kymera Therapeutics had 2 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Kymera Therapeutics and 2 mentions for Tyra Biosciences. Kymera Therapeutics' average media sentiment score of 1.39 beat Tyra Biosciences' score of 0.93 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kymera Therapeutics beats Tyra Biosciences on 9 of the 15 factors compared between the two stocks.

Get Tyra Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TYRA vs. The Competition

Export

Metric	Tyra Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.71B	$3.28B	$6.30B	$12.43B
Dividend Yield	N/A	2.36%	2.69%	5.33%
P/E Ratio	-12.47	18.46	24.03	24.35
Price / Sales	N/A	317.64	518.85	115.59
Price / Cash	N/A	111.03	41.39	55.53
Price / Book	5.59	6.77	9.98	6.72
Net Income	-$119.95M	$24.09M	$3.56B	$337.03M
7 Day Performance	-16.83%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	164.91%	48.90%	28.76%	33.98%

Tyra Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TYRA Tyra Biosciences	2.669 of 5 stars	$27.18 -5.3%	$46.50 +71.1%	+197.3%	$1.71B	N/A	N/A	20
QGEN Qiagen	4.0398 of 5 stars	$35.47 +0.9%	$44.98 +26.8%	-23.5%	$7.31B	$2.09B	18.52	5,654
PCVX Vaxcyte	2.775 of 5 stars	$50.11 +5.9%	$86.00 +71.6%	+35.4%	$7.24B	N/A	N/A	160	Insider Trade
IMVT Immunovant	2.09 of 5 stars	$33.83 -0.9%	$37.33 +10.4%	+101.7%	$6.95B	N/A	N/A	120
LNTH Lantheus	2.0809 of 5 stars	$100.06 -2.9%	$99.71 -0.3%	+29.0%	$6.71B	$1.55B	24.11	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TYRA) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tyra Biosciences (TYRA) Competitors

TYRA vs. QGEN, PCVX, IMVT, LNTH, and KYMR

How does Tyra Biosciences compare to Qiagen?

Summary

How does Tyra Biosciences compare to Vaxcyte?

Summary

How does Tyra Biosciences compare to Immunovant?

Summary

How does Tyra Biosciences compare to Lantheus?

Summary

How does Tyra Biosciences compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tyra Biosciences (TYRA) Competitors

TYRA vs. QGEN, PCVX, IMVT, LNTH, and KYMR

How does Tyra Biosciences compare to Qiagen?

Is QGEN or TYRA more profitable?

Which has more volatility and risk, QGEN or TYRA?

Which has higher earnings & valuation, QGEN or TYRA?

Do analysts recommend QGEN or TYRA?

Do insiders & institutionals have more ownership in QGEN or TYRA?

Does the media favor QGEN or TYRA?

Summary

How does Tyra Biosciences compare to Vaxcyte?

Which has more volatility and risk, PCVX or TYRA?

Do institutionals & insiders believe in PCVX or TYRA?

Does the media prefer PCVX or TYRA?

Is PCVX or TYRA more profitable?

Do analysts rate PCVX or TYRA?

Which has stronger earnings and valuation, PCVX or TYRA?

Summary

How does Tyra Biosciences compare to Immunovant?

Is TYRA or IMVT more profitable?

Do institutionals and insiders hold more shares of TYRA or IMVT?

Which has preferable earnings and valuation, TYRA or IMVT?

Which has more volatility & risk, TYRA or IMVT?

Does the media favor TYRA or IMVT?

Do analysts rate TYRA or IMVT?

Summary

How does Tyra Biosciences compare to Lantheus?

Which has higher earnings & valuation, LNTH or TYRA?

Do analysts prefer LNTH or TYRA?

Does the media prefer LNTH or TYRA?

Which has more risk & volatility, LNTH or TYRA?

Is LNTH or TYRA more profitable?

Do institutionals & insiders have more ownership in LNTH or TYRA?

Summary

How does Tyra Biosciences compare to Kymera Therapeutics?

Is TYRA or KYMR more profitable?

Which has more risk & volatility, TYRA or KYMR?

Do analysts rate TYRA or KYMR?

Do institutionals and insiders have more ownership in TYRA or KYMR?

Which has higher valuation and earnings, TYRA or KYMR?

Does the media refer more to TYRA or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools